Aurora Cannabis Must Prove Its Reset Year Has Bottomed After An 88% Rally

Aurora Cannabis enters its fiscal second-quarter report with an unusual mismatch between fundamentals and the stock chart. Last quarter management called the period the trough of a planned reset year, as a roughly 30% cut to Canadian veterans' medical reimbursement rates hit revenue, margins and cash flow at once. Since then the shares have climbed nearly 88% while the S&P 500 slipped. When the company reports before the open on November 12, the question is whether the promised rebound off the bottom is real enough to justify that move.

The Street is not asking for much. Consensus calls for a loss of $0.03 per share, compared with a $0.04 profit last quarter and $0.09 a year ago, a swing of roughly 133% lower on a year-over-year basis. Revenue is expected at $52.5 million, down about 20% from $65.6 million in the year-ago quarter but slightly above last quarter's $51.1 million. That modest sequential gain stands out. Management said second-quarter revenue and adjusted EBITDA should come in substantially higher than the first quarter. Consensus implies only a low single-digit revenue increase, so either analysts doubt the guidance or they have left room for an upside surprise. A print that clearly beats last quarter would support management's claim that the worst is over. A flat result would undercut it.

The swing factor is the international medical business, which now carries the company. International medical revenue grew 17% last quarter, led by Germany. That continued a run of high-teens to low-20s growth, and non-Canadian sales reached 64% of the mix, up from 50% a year earlier. Holding that pace matters, but so does how it is earned. Management flagged price pressure in Germany's value segment from new entrants, plus possible German rules on telehealth and mail delivery that were expected to take shape this fall. Growth that holds up without heavier discounting would ease concern about both. Any update on those regulations could matter as much as the quarter's numbers.

Margins are the second test. Adjusted gross margin fell to 58% last quarter, well below the 64% posted for fiscal 2026 and the high-60s medical margins seen at the peak. Adjusted EBITDA dropped to $3.4 million, and free cash flow turned negative. Several of management's own catalysts should help here. The Safari Flower acquisition was already adding to EBITDA and now has three years of EU GMP certification. The expansion at Loina in Germany, which was nearing completion, is expected to double that site's flower output. If that extra capacity is ramping, it should show up as better gross margin on a larger international base. Even a few points of recovery would help confirm that the first quarter was the bottom. Further slippage would suggest the reimbursement cut is not the only pressure.

Cash is worth watching as well. Aurora carries no debt and held about $150 million, down from $165 million the prior quarter. A return to breakeven or positive free cash flow would reinforce its defensive appeal. Another outflow would make that balance sheet a bigger part of the investment case than investors would like.

Sentiment has warmed, rising to 32.4% bullish from 23.8% ahead of the last report. The stock trades at $5.16, far above its 200-day average of $3.55 and just below its post-earnings high of $5.20, so it is testing a breakout. That leaves little cushion. Part of the rally likely reflects early optionality around US rescheduling, which management raised only as a longer-term possibility. In the end, the report comes down to one issue: whether second-quarter revenue and EBITDA rise enough to confirm the trough, with Germany and the new capacity offsetting Canada. Without that, the reset-year story stays intact on paper but loses the momentum the stock has already priced in.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.